On October 8, Regeneron Pharmaceuticals Inc. said it has asked federal regulators to authorize its antibody treatment for COVID-19 for emergency use. It shared gained more than 1% in midday trading in New York, and rose in after-hours trading.
Regeneron Pharmaceuticals Inc.’s antibody cocktail declared that it received an extremity use authorization from U.S. drug transformers for treatment of early Covid-19 symptoms, attaching to the enlarging arsenal of therapies accessible to physicians.
received the antibody cocktail on October under a compassionate use program after becoming sick with the corona virus. In a statement yesterday, the U.S. Food and Drug Administration said, “In a clinical trial of patients with Covid-19, casirivimab and imdevimab, administered together, were shown to reduce Covid-19-related hospitalization or emergency room visits in patients at high risk for disease progression within 28 days after treatment when compared to placebo.” “The safety and effectiveness of this investigational therapy for use in the treatment of Covid-19 continues to be evaluated.”
Commissioner Stephen Hahn said, “The FDA remains committed to advancing the nation’s public health during this unprecedented pandemic.” “Authorizing these monoclonal antibody therapies may help outpatients avoid hospitalization and alleviate the burden on our health care system.”